concept

AMYLOID PATHOLOGY

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about AMYLOID PATHOLOGY: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

63Connections

1Hypotheses

8Analyses

10Outgoing

50Incoming

0Experiments

12Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	AMYLOID PATHOLOGY

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

amyloid-pathology

mechanism · 758 words

→

Pathway Diagram

graph TD
    AMYLOID_PATHOLOGY["AMYLOID PATHOLOGY"]
    AMYLOID_PATHOLOGY -->|"involved_in"| Alzheimer_S_Disease["Alzheimer'S Disease"]
    AMYLOID_PATHOLOGY -.biomarker for.-> Alzheimer_s_Disease["Alzheimer's Disease"]
    AMYLOID_PATHOLOGY -->|"interacts"| Neuroinflammation["Neuroinflammation"]
    AMYLOID_PATHOLOGY -->|"interacts"| mitochondrial_dysfunction["mitochondrial dysfunction"]
    Ptau217["Ptau217"] -.biomarker for.-> AMYLOID_PATHOLOGY
    ABETA42["ABETA42"] -->|"component_of"| AMYLOID_PATHOLOGY
    ABETA40["ABETA40"] -->|"component_of"| AMYLOID_PATHOLOGY
    APOE4["APOE4"] -->|"causes"| AMYLOID_PATHOLOGY
    APOE3["APOE3"] -.protects against.-> AMYLOID_PATHOLOGY
    Oligodendrocytes["Oligodendrocytes"] -->|"interacts"| AMYLOID_PATHOLOGY
    Anti_Amyloid_Immunotherapy["Anti-Amyloid Immunotherapy"] -->|"targets"| AMYLOID_PATHOLOGY

Outgoing (10)

Target	Relation	Type	Str
Alzheimer's Disease	drives	disease	0.95
Alzheimer'S	biomarker_for	disease	0.95
Alzheimer'S Disease	involved_in	disease	0.90
ALZHEIMER'S DISEASE	associated_with	entity	0.90
Alzheimer's Disease	biomarker_for	disease	0.85
Tau Pathology	associated_with	phenotype	0.80
Neuroinflammation	interacts_with	process	0.80
Alzheimer's Disease	contributes_to	disease	0.79
mitochondrial dysfunction	interacts_with	process	0.70
microglial metabolic reprogramming	causes	mechanism	0.70

Incoming (53)

Source	Relation	Type	Str
ABETA42	component_of	protein	0.95
Ptau217	biomarker_for	biomarker	0.95
ABETA40	component_of	protein	0.95
APOE3	protects_against	protein	0.90
APOE4	upregulates	protein	0.90
35320002	induced by	paper	0.90
APOE4	causes	protein	0.90
Anti-Amyloid Immunotherapy	targets	drug	0.90
Lipopolysaccharide	activates	compound	0.90
Dazucorilant	treats	drug	0.90
Lecanemab	targets	drug	0.90
Donanemab	targets	drug	0.90
donanemab	inhibits	drug	0.90
lecanemab	inhibits	drug	0.90
Oligodendrocytes	interacts_with	cell_type	0.90
APOE*ε4 allele	drives	phenotype	0.90
CD33	involved_in	gene	0.85
BOK Overexpression	associated_with	mechanism	0.85
Glymphatic Failure	precedes	process	0.85
BDNF	associated_with	protein	0.85
TIMP3	associated_with	protein	0.85
Glymphatic System Dysfunction	precedes	process	0.85
Disease-associated microglia	regulates	cell_type	0.85
Positron Emission Tomography	involved_in	process	0.80
J20 Mouse Model	associated_with	cell_type	0.80
5Xfad Mouse Model	associated_with	cell_type	0.80
Nr3C1 Inhibition	protects_against	mechanism	0.80
Glucocorticoid Receptor	involved_in	receptor	0.80
FGF2	upregulates	protein	0.80
BDNF	downregulates	protein	0.80
IL9	upregulates	protein	0.80
IL4	upregulates	protein	0.80
Neural Cell Culture Model	associated_with	cell_type	0.80
IL4	biomarker_for	protein	0.80
IL9	biomarker_for	protein	0.80
FGF2	biomarker_for	protein	0.80
TREM2	modulates	gene	0.75
Chronic Inflammation	associated_with	process	0.75
DNA damage	precedes	process	0.70
oligodendrocyte DNA damage	precedes	process	0.70
TREM2 activation	inhibits	process	0.70
cholesterol reduction	modulates	process	0.70
24S-hydroxycholesterol	prevents	biomarker	0.70
cholesterol	regulates	biomarker	0.70
UPR modulation	reduces	process	0.70
P2RX7 deficiency	causes	process	0.70
Trem2 deletion	prevents	process	0.70
PPARA AGONISTS	decreases	drug	0.70
Neuroinflammation	interacts_with	process	0.70
Depression	modulates	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate	0.785	-	Do β-amyloid plaques and neurofibrillary

Mentioning Analyses (8)

Scientific analyses that reference this entity

What is the minimum effective dose of trazodone required for disease-modifying e

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.605

Why have numerous phase 3 clinical trials failed despite advances in understandi

neurodegeneration | 2026-04-12 | 1 hypotheses Top: 0.566

What are the molecular signatures that distinguish protective vs. harmful microg

neurodegeneration | 2026-04-12 | 0 hypotheses

How can circuit-level neurodegeneration mechanisms be identified without complet

research methodology | 2026-04-11 | 0 hypotheses

Do P2RX7 antagonists selectively block pathogenic exosomes while preserving bene

neurodegeneration | 2026-04-11 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (12)

Multi-agent debates referencing this entity

Extended debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: Membrane Cholesterol Gradient Modulators

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

What is the minimum effective dose of trazodone required for disease-modifying e

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

The debate proposed biphasic TREM2 modulation but couldn't define when to switch

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

The debate highlighted P2RX7's dual role in both harmful exosome secretion and b

closed · Rounds: 4 · Score: 1.00 · 2026-04-20

The debate transcript shows incomplete analysis where the Theorist reached maxim

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

The debate transcript shows incomplete information exchange, suggesting this fun

closed · Rounds: 4 · Score: 0.49 · 2026-04-18

Why have numerous phase 3 clinical trials failed despite advances in understandi

closed · Rounds: 5 · Score: 0.67 · 2026-04-12

Related Research

Hypotheses and analyses mentioning AMYLOID PATHOLOGY in their description or question text

No additional research found

AMYLOID PATHOLOGY

Understanding Entity Pages

Wiki Pages (1)

amyloid-pathology

Pathway Diagram

Outgoing (10)

Incoming (53)

Targeting Hypotheses (1)

Mentioning Analyses (8)

What is the minimum effective dose of trazodone required for disease-modifying e

Why have numerous phase 3 clinical trials failed despite advances in understandi

What are the molecular signatures that distinguish protective vs. harmful microg

How can circuit-level neurodegeneration mechanisms be identified without complet

Do P2RX7 antagonists selectively block pathogenic exosomes while preserving bene

What are the optimal temporal windows for TREM2 inhibition vs activation in Alzh

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

Lipid raft composition changes in synaptic neurodegeneration

Experiments (0)

Related Papers (0)

Debates (12)

Extended debate: CYP46A1 Overexpression Gene Therapy

Hypothesis debate: Membrane Cholesterol Gradient Modulators

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

What is the minimum effective dose of trazodone required for disease-modifying e

The debate proposed biphasic TREM2 modulation but couldn't define when to switch

The debate highlighted P2RX7's dual role in both harmful exosome secretion and b

The debate transcript shows incomplete analysis where the Theorist reached maxim

The debate transcript shows incomplete information exchange, suggesting this fun

Why have numerous phase 3 clinical trials failed despite advances in understandi

Related Research